Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR2 amp||colorectal cancer||predicted - sensitive||Regorafenib||Preclinical - Cell culture||Actionable||In a preclinical study, Stivarga (regorafenib) inhibited Fgfr2 signaling and proliferation of FGFR2-amplified colorectal cancer cells in culture (PMID: 29573334).||29573334|
|FGFR2 amp||colorectal cancer||predicted - sensitive||Regorafenib||Preclinical - Cell culture||Actionable||In a preclinical study, a colorectal cancer cell line with FGFR1 and FGFR2 amplification was sensitive to treatment with Stivarga (regorafenib), demonstrating inhibition of cell growth in culture (PMID: 33563752).||33563752|
|PubMed Id||Reference Title||Details|
|(29573334)||FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro.||Full reference...|
|(33563752)||Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK.||Full reference...|